论文部分内容阅读
目的分析杭州地区肺腺癌患者中EGFR、KRAS与BRAF基因的突变情况,并探讨其在肺腺癌个体化诊断和治疗中的临床应用价值。方法采用实时荧光定量PCR法检测患者肿瘤组织中EGFR、KRAS与BRAF突变情况。结果 89例肺腺癌患者中有47例存在EGFR基因突变,突变率为52.8%,19外显子和21外显子分别占突变总数的42.6%(20/47)和57.4%(27/47),20外显子T790M突变1例。KRAS突变率为3.3%(3/89),未检出BRAF突变。女性患者EGFR基因突变率(77.5%)高于男性患者(26.5%),不吸烟患者突变率(64.9%)高于吸烟患者(31.3%),差异均有统计学意义(P<0.05)。结论在使用靶向治疗药物之前,应检测EGFR、KRAS和BRAF等基因的突变情况,依据基因突变结果制定个性化治疗方案。
Objective To analyze the mutations of EGFR, KRAS and BRAF genes in patients with lung adenocarcinoma in Hangzhou and to explore their clinical value in the individual diagnosis and treatment of lung adenocarcinoma. Methods The changes of EGFR, KRAS and BRAF in tumor tissue were detected by real-time fluorescence quantitative PCR. Results Of the 89 patients with lung adenocarcinoma, 47 patients had EGFR gene mutation, the mutation rate was 52.8%, 19 exon and 21 exon accounted for 42.6% (20/47) and 57.4% (27/47 ), 20 exons T790M mutation in 1 case. The KRAS mutation rate was 3.3% (3/89) and no BRAF mutation was detected. The mutation rate of EGFR gene was higher in female patients (77.5%) than in male patients (26.5%), while the non-smoking patients (64.9%) was higher than that in smokers (31.3%) (P <0.05). Conclusion Before using targeted therapy, the mutation of EGFR, KRAS and BRAF genes should be detected and the personalized treatment plan should be formulated based on the gene mutation results.